| Reference |
Sentence |
Publish Date |
Extraction Date |
Species |
| Qian Li, Yun'Ai Su, Xuemei Liao, Maosheng Fang, Jianliang Gao, Jia Xu, Mingjun Duan, Haiying Yu, Yang Yang, Zhiyu Chen, Jintong Liu, Shaoxiao Yan, Peifen Yao, Shuying Li, Changhong Wang, Bin Wu, Congpei Zhang, Tianmei S. Aripiprazole in the treatment of acute episode of schizophrenia: a real-world study in China. Chinese medical journal vol issue 2023 37014776 |
aripiprazole in the treatment of acute episode of schizophrenia: a real-world study in china. |
2023-04-04 |
2023-04-07 |
Not clear |
| Claudio Brasso, Gianluca Colli, Rodolfo Sgro, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni, Vincenzo Villari, Paola Rocc. Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review. Biomedicines vol 11 issue 3 2023 36979900 |
serotonin-dopamine activity modulators (sdams), of which aripiprazole, cariprazine, brexpiprazole, and lumateperone were approved for schizophrenia treatment, represent a possible therapy to reduce ns. |
2023-03-29 |
2023-04-11 |
Not clear |
| Matthew Harlin, Murat Yildirim, Pedro Such, Jessica Madera-McDonough, Michael Jan, Na Jin, Suzanne Watkin, Frank Larse. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. CNS drugs vol issue 2023 36961650 |
a randomized, open-label, multiple-dose, parallel-arm, pivotal study to evaluate the safety, tolerability, and pharmacokinetics of aripiprazole 2-month long-acting injectable in adults with schizophrenia or bipolar i disorder. |
2023-03-24 |
2023-04-07 |
Not clear |
| Matthew Harlin, Murat Yildirim, Pedro Such, Jessica Madera-McDonough, Michael Jan, Na Jin, Suzanne Watkin, Frank Larse. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. CNS drugs vol issue 2023 36961650 |
aripiprazole 2-month ready-to-use 960 mg (ari 2mrtu 960) is a new long-acting injectable antipsychotic formulation for gluteal administration every 2 months, currently being investigated for the treatment of schizophrenia and bipolar i disorder (bp-i). |
2023-03-24 |
2023-04-07 |
Not clear |
| Matthew Harlin, Murat Yildirim, Pedro Such, Jessica Madera-McDonough, Michael Jan, Na Jin, Suzanne Watkin, Frank Larse. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. CNS drugs vol issue 2023 36961650 |
the objectives of this trial were to evaluate the safety and tolerability of ari 2mrtu 960, and the similarity of aripiprazole plasma concentrations following administration of ari 2mrtu 960 or aripiprazole once-monthly 400 mg (aom 400), in adults with schizophrenia or bp-i. |
2023-03-24 |
2023-04-07 |
Not clear |
| Daniel Sch\\xc3\\xb6ttle, Wolfgang Janetzky, Francois Therrien, Klaus Wiedeman. BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study). BMC psychiatry vol 23 issue 1 2023 36918846 |
bprs domains, items and subgroups analyses, and cgi-i ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (react study). |
2023-03-15 |
2023-04-07 |
Not clear |
| Ruth Milz, Carmela Benson, Karl Knight, Jose Antunes, Dean Najarian, Paola-Maria Lopez Rengel, Steven Wang, Ute Richarz, Srihari Gopal, John M Kan. The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia. Neuropsychiatric disease and treatment vol 19 issue 2023 36915909 |
aripiprazole lauroxil and paliperidone palmitate three-monthly (pp3m) lais have longer dosing intervals of 2-3 months and provide improved outcomes in patients with schizophrenia. |
2023-03-14 |
2023-04-07 |
Not clear |
| Saki Hattori, Akira Suda, Ikuko Kishida, Masatoshi Miyauchi, Yohko Shiraishi, Nobuhiko Noguchi, Taku Furuno, Takeshi Asami, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Takashi Saeki, Tadashi Fukushima, Toshio Moritani, Yusuke Saigusa, Akitoyo Hishimot. Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. BMC psychiatry vol 23 issue 1 2023 36869320 |
differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. |
2023-03-03 |
2023-03-06 |
Not clear |
| Saki Hattori, Akira Suda, Ikuko Kishida, Masatoshi Miyauchi, Yohko Shiraishi, Nobuhiko Noguchi, Taku Furuno, Takeshi Asami, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Takashi Saeki, Tadashi Fukushima, Toshio Moritani, Yusuke Saigusa, Akitoyo Hishimot. Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. BMC psychiatry vol 23 issue 1 2023 36869320 |
among them, oral aripiprazole has been linked to dysfunction of the ans in schizophrenia. |
2023-03-03 |
2023-03-06 |
Not clear |
| Saki Hattori, Akira Suda, Ikuko Kishida, Masatoshi Miyauchi, Yohko Shiraishi, Nobuhiko Noguchi, Taku Furuno, Takeshi Asami, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Takashi Saeki, Tadashi Fukushima, Toshio Moritani, Yusuke Saigusa, Akitoyo Hishimot. Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. BMC psychiatry vol 23 issue 1 2023 36869320 |
in this study, we compared ans activity between oral aripiprazole and aripiprazole once-monthly (aom) in schizophrenia. |
2023-03-03 |
2023-03-06 |
Not clear |
| Heidi C Waters, Robert Stellhorn, Maelys Touya, Heather Fitzgerald, Sandipan Bhattacharjee, Leslie Citrom. The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data. Journal of medical economics vol issue 2023 36780296 |
the effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from us claims data. |
2023-02-13 |
2023-03-06 |
Not clear |
| Heidi C Waters, Robert Stellhorn, Maelys Touya, Heather Fitzgerald, Sandipan Bhattacharjee, Leslie Citrom. The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data. Journal of medical economics vol issue 2023 36780296 |
to evaluate the impact of timing of aripiprazole once-monthly (aom) initiation on healthcare resource utilization (hcru), risk of hospitalization, and healthcare costs in patients with schizophrenia. |
2023-02-13 |
2023-03-06 |
Not clear |
| Chittaranjan Andrad. Prolactin-Raising and Prolactin-Sparing Antipsychotic Drugs and the Risk of Fracture and Fragility Fracture in Patients With Schizophrenia, Dementia, and Other Disorders. The Journal of clinical psychiatry vol 84 issue 1 2023 36724110 |
an observational study that controlled for confounding by indication and illness severity found that fragility fractures in patients with schizophrenia were associated with higher daily doses, higher cumulative doses, longer duration of treatment, and prolactin-raising rather than prolactin-sparing antipsychotics; in patients receiving prolactin-raising antipsychotics, the concurrent use of aripiprazole appeared protective. |
2023-02-01 |
2023-03-06 |
Not clear |
| Heidi C Waters, Maelys Touya, Soon Nan Wee, Michelle Ng, Simran Thadani, Subina Surendran, Miguel Renter\\xc3\\xada, A John Rush, Rashmi Patel, Joydeep Sarkar, Heather M Fitzgerald, Xue Ha. Psychiatric healthcare resource utilization following initiation of aripiprazole once-monthly: a retrospective real-world study. Current medical research and opinion vol 39 issue 2 2023 36380678 |
this observational retrospective real-world study examined changes in healthcare resource utilization (hcru) pre- and post-initiation of aripiprazole once-monthly (aom 400) in patients with schizophrenia or bipolar i disorder. |
2023-01-30 |
2023-01-31 |
Not clear |
| Yusuke Okada, Ken Inada, Manabu Akazaw. Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan. Schizophrenia research vol 252 issue 2023 36706475 |
to compare the effectiveness of different long-acting injectable antipsychotics (lais) (aripiprazole, paliperidone, risperidone, and fluphenazine/haloperidol) in patients with schizophrenia in japan. |
2023-01-27 |
2023-01-31 |
Not clear |
| Sung-Wan Kim, Bong-Ju Lee, Eun-Jin Cheon, Seung-Hee Won, Anna Jo, Jae-Min Kim, Young-Chul Chun. Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol 21 issue 1 2023 36700312 |
effectiveness of switching to long-acting injectable aripiprazole in patients with recent-onset and chronic schizophrenia. |
2023-01-26 |
2023-01-31 |
Not clear |